April 2016 in “The Journal of Sexual Medicine” This report analyzed an FDA adverse event database and aimed to evaluate and describe post-finasteride syndrome potentially related to dutasteride, but it does not report new clinical findings.
30 citations
,
January 2020 in “Fertility and Sterility” This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.
8 citations
,
May 2016 in “Indian Journal of Pharmacology” This case report describes an atypical postfinasteride syndrome in a patient treated with both dutasteride and finasteride for androgenic alopecia, highlighting its multisystem involvement and irreversible nature.
2 citations
,
March 2016 in “The Journal of Urology” This study found that the 1 mg dose of finasteride was associated with a wide range of adverse effects, including sexual, psychological, and metabolic symptoms, in the FAERS data.
May 2021 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” This article evaluates clinical and scientific literature on post-finasteride syndrome, concluding that finasteride and dutasteride may cause persistent sexual, neurological, and physical adverse side effects in a subset of men.